Tc-99m MIBI MAMMOSCINTIGRAPHY A FUNCTIONAL IMAGING FOR BREAST CANCER
Abstract
Drug resistance of malignant cells is a major cause of failure in cancer chemotherapy. Multidrug resistance (MDR) mediated by the transmembrane pump P-glycoprotein (Pgp) is an important mechanism of tumor resistance against chemotherapy. Recent study by Ciarmiello et al reported that Tc-99m MIBI efflux from the breast cancers with high levels of Pgp was significantly faster than that observed in cancers with low Pgp levels. The purpose of our study was to evaluate the pattern and characteristic of Tc-99m MIBI uptake in the breast cancers.
Downloads
Metrics
References
Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug- resistant P-glycoprotein with an organo- technetium complex. Cancer Res 1993;53:- 977-84.
Ballinger JR, Hua HA, Berry BW, et al. Tc-99m sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resis- tance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin- resistant variant.Nucl Med Commun 1995;- 16:253-7.
Wackers FJ, Berman DJ, Maddahi J, et al. Technetium-99m-hexakis - 2-methoxyiso- butyl isonitrile: human biodistribution, dosimetry, safety and preliminary com- parison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:- 301-11.
Hassan IM, Sahweil A, Constantinides C, et al. Uptake and kinetics of Tc-99m-hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions of the lungs. Clin Nucl Med 1989; 14: 333-40.
Caner B, Kitapci M, Aras T, et al. Increased accumulation of hexakis (2-methoxyisobu- tylisonitrile) technetium (I) in osteosarcoma and its metastatic lymph nodes. J Nucl Med 1991; 32: 1977-8.
Taillefer R, Boucher Y, Potvin C, et al. Detection and localization of parathyroid adenomas in patients with hyperparathyroi- dism using a single radionuclide imaging procedure with Technetium-99m-Sestamibi (double-phase study). J Nucl Med 1992;33:- 1801-7.
Bagni B, Pinna L, Tamarozzi R, et al. SPET imaging of intracranial tumours with Tc- 99m-sestamibi. Nucl Med Com 1995;16:- 258-64.
Campeau RJ, Kronemer KA, Sutherland CM. Concordant uptake of Tc-99m Sestamibi and T1-201 in unsuspected breast tumor. Clin Nucl Med 1992;17:936-7.
Khalkhali I, Cutrone JA, Mena IG, et al. Scintimammography: The complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carci- noma. Radiology 1995;196:421-6.
Khalkhali I, Mena I, Diggles L. Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scinti- mammography using technetium-99m sestamibi. Eur J Nucl Med 1994;21:57-62.
Taillefer R, Robidoux A, Lambert R, et al. Technetium-99m-Sestamibi prone scinti- mammography to detect primary breast cancer and axillary lymph node involve- ment. J Nucl Med 1995;36:1758-65.
Khalkhali I, Cutrone J, Mena I, et al. Technetium-99m Sestamibi scintimam- mography of breast lesions: Clinical and pathological follow-up. J Nucl Med 1995;- 36:1784-9.
Palmedo H, Schonburg A, Grunwald F, et al. Technetium-99m MIBI scintimammo- graphy for suspicious breast lesions. J Nucl Med 1996;37:626-30.
Villanueva-Meyer J, leonard Jr MH, Briscoe E, et al. Mammoscintigraphy with techne- tium-99m Sestamibi in suspected breast cancer. J Nucl Med 1996;37:926-30.
Khalkhali I, Cutrone J, Mena I, et al. Clinical and pathologic follow-up of 100 patients with breast lesions studied with scintimam- mography [abstract]. J Nucl Med 1994;- 35:22P.
Waxman A, Nagaraj N, Ashok G, et al. Sensitivity and specificity of Tc-99m methoxy isobutyl isonitrile (MIBI) in the evaluation of primary carcinoma of the breast: comparison of palpable and non- palpable lesions with mammography [abstract]. J Nucl Med 1994;35:22P.
Palmedo H, Grunwald F, Bender H, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging. Eur J Nucl Med 1996;23:940-6.
Rao VV, Chiu ML, Kronauge JF, et al. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of Technetium-99m-Sestamibi. J Nucl Med 1994;35:510-15.
Cordobes MD, Starzec A, Delmon- Moingeon L, et al. Technetium-99m Sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression. J Nucl Med 1996;37:286-9.
Ciarmiello A, Del Vecchio S, Potena MI, et al. Tc-99m Sestamibi efflux and P-glyco- protein expression in human breast carci- noma [abstract]. J Nucl Med 1995;36:129P.
Derebek E, Kirkali Z, Dogan AS, et al. Tc- 99m MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between Tc-99m MIBI uptake and P-glycoprotein expression in tumour tissue. Eur J Nucl Med 1996;23:976-9.
Crane P, Laliberte R, Heminway S. Effect of mitochondrial viability and metabolism of technetium-99m-sestamibi. Eur J Nucl Med 1993;20:20-25.
Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis-(alkylisonitrile) technetium-99m complexes. J Nucl Med 1990;31:1166-7.
Lum BL, Fisher GA, Brophy NA. Clinical trials of modulation of multidrug resistance: pharmacokinetic and pharmacodynamic considera-tions. Cancer 1993;72 Suppl:- 3502-14.
Moretti JL, Azaloux H, Boisseron D, et al. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med 1996;23:980-6.
Kao CH, Wang SJ, Yeh SH. Tc-99m MIBI uptake in breast carcinoma and axillary lymph node metastases. Clin Nucl Med 1994;19:898-900.
Lam WWM, Yang WT, Chan YL, et al. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography. Eur J Nucl Med 1996;23:498-503.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 The ASEAN Journal of Radiology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Disclosure Forms and Copyright Agreements
All authors listed on the manuscript must complete both the electronic copyright agreement. (in the case of acceptance)
